Fig. 3: Increased osteogenic differentiation capacity and decreased adipogenic differentiation capacity in MSCs from patients with active cGVHD. | Cell Death & Disease

Fig. 3: Increased osteogenic differentiation capacity and decreased adipogenic differentiation capacity in MSCs from patients with active cGVHD.

From: Wnt/β-catenin signaling mediates the abnormal osteogenic and adipogenic capabilities of bone marrow mesenchymal stem cells from chronic graft-versus-host disease patients

Fig. 3

A Osteogenic differentiation (above) of HD-MSCs, no cGVHD-MSCs, mild cGVHD-MSCs and moderate/severe cGVHD-MSCs was demonstrated by alizarin red staining, Orange-red represents calcium nodules. Adipogenic differentiation (under) of HD-MSCs, no cGVHD-MSCs, mild cGVHD-MSCs, and moderate/severe cGVHD-MSCs was detected by Oil Red O staining, and red represents lipid droplets. Scar bar = 50 μm. B Gene expression of osteogenic markers RUNX2 and COL1A1 in HD-MSCs, no cGVHD-MSCs, active cGVHD-MSCs, and different severities of cGVHD-MSCs. C Gene expression of adipogenic markers PPAR-γ and FABP4 in HD-MSCs, no cGVHD-MSCs, active cGVHD-MSCs, and different severities of cGVHD-MSCs. HD-MSCs (n = 7), no cGVHD-MSCs (n = 33), mild cGVHD-MSCs (n = 8), and moderate/severe cGVHD-MSCs (n = 25). Results were normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Black bars in each figure represent the median ± range. NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Back to article page